Pursue Era of Persistent Income: Select 3 Shares to Acquire Instantly and Keep Indefinitely
Gasp at the thought of owning a machine that churns out cash year after year, day after day. Well, you're in luck! Such "machines" do exist, and they're known as dividend stocks. And the best part? There's no need for wizardry or wishful thinking to get your hands on them.
Dividend stocks can be your ticket to a steady stream of passive income for years to come. And if that's not enough, you're in for a treat - these stocks have got a fantastic track record of delivering the goods. Without further ado, here are three divvy-dishing stocks to add to your investment portfolio and keep forever:
1. AbbVie
Hold tight for a tried and true standout - AbbVie. This pharmaceutical powerhouse is offering a forward dividend yield of 3.2% at the moment. And let me tell you, the cherry on top is AbbVie's esteemed dividend track record. This player has shown its prowess by increasing its dividend for an impressive 52 years in a row, earning it a spot amid the investment elite's club: the Dividend Kings.
Now, you might be thinking, "Dang, that's impressive, but what if their flagship product, Humira, loses patent protection?" No sweat! AbbVie has got this. They've invested heavily in research and development and made thoughtful business moves. The result is two Humira successors currently on the market, set to generate even more collective sales by 2027 than Humira did at its peak. It's safe to say that AbbVie is a resilient stock that can span the test of time and provide you with a dependable source of passive income for decades.
2. Brookfield Infrastructure
Up next, pull up a chair for Brookfield Infrastructure. This operation kingpin is as sturdy as they come. With a wide range of business operations—from data centers to electricity transmission lines—Brookfield Infrastructure boasts a stable cash flow. And get this: about 85% of its funds from operations (FFO) are contracted or regulated. Plus, more than 85% of its distributions are safeguarded against inflation.
What does this mean for you? A reliable and dependable, growing passive income stream. Brookfield Infrastructure has been on a rising streak since 2004 with a 9% compound annual growth rate (CAGR) in its distribution. And its yields aren't all that shabby: the limited partnership trading under the BIP ticker offers a forward yield of 5.3%, while the corporate entity under BIPC's ticker boasts a forward yield of roughly 4%.
But that's not all, buddy. Brookfield Infrastructure has got a solid expansion plan in action. They snatch up infrastructure assets when the prices are right and make improvements to increase their value. By recycling mature assets, they'll keep the growth cycle going strong.
3. Realty Income
Last but not least, take a ride to the realm of Realty Income. Want to put some serious cash in your pocket? Realty Income delivers a forward yield of 5.8% as we speak. And here's where it gets even better—this real estate investment trust (REIT) has a 30-year streak of increasing its dividend. Not to mention, the dividend growth comes in at an impressive 4.3% compound annual growth rate (CAGR) during that period.
Now, this isn't your average run-of-the-mill REIT. Realty Income has made a name for itself as a heavyweight, ranking as the 7th-largest REIT in the world. It commands over 15,000 properties leased to 1,500+ clients in various industries. Around a third of its annual rental income comes from folks who know how to ride out the waves: convenience, grocery, discount, and home improvement store giants.
No wonder this machine doesn't miss a beat, even when the economy takes a tumble. This means you can count on a steady passive income stream, though maybe not one that'll knock your socks off with explosive growth. Realty Income has its sights set on the $5.4 trillion total addressable market in the U.S. and $8.5 trillion in Europe, with growth opportunities in freestanding retail, industrial, and data center properties.
- In the world of finance, dividend stocks like AbbVie are considered valuable, offering a steady income source with a forward dividend yield of 3.2%.
- With a robust track record, AbbVie has increased its dividend for an impressive 52 years consecutively, securing a place among the financial elite called the Dividend Kings.
- Despite concerns about patent protection for its flagship product Humira, AbbVie has reinforced its position by investing heavily in research and development, introducing two Humira successors to the market.
- In terminals of autoimmune disease research, AbbVie's resilience and commitment to innovation ensure a dependable source of passive income for investors for decades to come.
